RT Journal Article
SR Electronic
T1 COVID-19 vaccination coverage and linkages with public willingness to receive vaccination prior to vaccine roll-out: Evidence from Rwanda
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.05.23286509
DO 10.1101/2023.03.05.23286509
A1 Ndishimye, Pacifique
A1 Martinez, Gustavo S.
A1 Hewins, Benjamin
A1 Ostadgavahi, Ali Toloue
A1 Kumar, Anuj
A1 Sharma, Mansi
A1 Karuhije, Janvier
A1 Nkeshimana, Menelas
A1 Nsanzimana, Sabin
A1 Kelvin, David
YR 2023
UL http://medrxiv.org/content/early/2023/03/06/2023.03.05.23286509.abstract
AB The rapid development of multiple SARS-CoV-2 vaccines within one year of the virus’s emergence is unprecedented and redefines the timeline for vaccine approval and rollout. Consequently, over 13 billion COVID-19 vaccine doses have been administered worldwide, accounting for ∼70% of the global population. Despite this steadfast scientific achievement, many inequalities exist in vaccine distribution and procurement, particularly in low- and middle-income countries such as those in Africa. This stems from the cost of COVID-19 vaccines, storage and cold-chain challenges, distribution to remote areas, proper personnel training, and so on. In addition to logistical challenges, many developed nations rapidly procured available vaccines, administering second and third doses and leaving many developing nations without the first dose. In this paper, we explore the level of reception to COVID-19 vaccines prior to their availability in Rwanda using a survey-based approach. While several countries reported spikes in vaccine hesitancy generally coinciding with new information, new policies, or newly reported vaccine risks, Rwanda functions as an exemplar for controlling disease burden and educating locals regarding the benefits of vaccination. We show that, even before COVID-19 vaccines were available, many Rwandans (97%) recognized the importance of COVID-19 vaccination and (93%) were willing to receive a COVID-19 vaccine following vaccine availability. Our results underscore the level of preparedness in Rwanda, which rivals and outcompetes many developed nations in terms of vaccination rate (nearing 80% in Rwanda), vaccine acceptance, and local knowledge relating to vaccination. Furthermore, in addition to the whole-of-government coordination as well as tailored delivery approach, previously developed practices relating to vaccination and communication surrounding the Ebola Virus Disease may have compounded the COVID-19 vaccine program in Rwanda, prior to its implementation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Canadian Institutes of Health Research, Genome Canada/Atlantic Genome, Research Nova Scotia, Dalhousie Medical Research Foundation, and the Li-Ka Shing Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clearance to conduct the research was obtained from the Rwanda National Ethics committee (No.938/RNEC/2020) as well as the Rwanda National Health Research Committee. The research team received a training demonstration on obtaining informed consent and the principles of ethical research as well as guidelines to protect the research and study participants from COVID-19. All participants signed a written consent form to participate in the study and that the results can be used for research purposes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesFor ethical reasons, raw data generated during the survey were not made publicly available. Access to the datasets analysed may be facilitated upon reasonable request to the corresponding author. However, the analysed data from JHU are available at: https://coronavirus.jhu.edu/. https://coronavirus.jhu.edu/